More News! 24 May 2017 Seed Funding for a German Cell Therapy to Prevent Transplant Rejection TolerogenixX has proved that it can get rid of immunosuppressants in organ transplants in Phase I and secured seed funding from High-Tech Gründerfonds. TolerogenixX is a startup from the Heidelberg University Hospital that develops personalized immunosuppression therapies. Its cell therapy technology has just passed Phase I, where it showed an “impressive efficacy” in preventing the rejection of […] May 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2017 UK biotech is catching up to the US, but will it run out of gas? The UK is far ahead of its European biotech rivals according to a new report, but will it fulfill its promise of becoming a global hub? According to analysis by the BioIndustry Association, the UK is catching up to global biotech leaders San Francisco and Boston, both in finance and R&D. British biotechs banked £1.13B last year, and […] May 24, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2017 French Biotech Enters New Agreement to Advance its IBD Immunotherapy OSE Immunotherapeutics has teamed up with Selexis in a new license agreement to support the development of its IL-7 antagonist for the treatment of IBD. In the end of last year, French OSE Immunotherapeutics joined forces with Servier to develop and commercialize its interleukin-7 antagonist (Effi-7) in a deal that could earn the biotech up […] May 24, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2017 Curious about Who is Living in Your Gut? This Kit Can Tell You Personalized and democratized medicine is coming to the microbiome via a new initiative, FeelGut, from Biopolis. The FeelGut kit lets you explore your gut! FeelGut is a new kit for those of us who want to explore their microbiota. It’s developed by Biopolis, a Spanish biotech committed to empowering people through improved understanding and control of […] May 24, 2017 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 24 May 2017 What Happens when the Immune System Attacks Life-Saving Drugs? Immunogenicity has been largely disregarded despite its huge impact on the performance of biological drugs. What is it and how can we fight it? Immunogenicity can be a huge problem. Affecting especially protein-based drugs, this process consists in the development of anti-drug antibodies (ADAs) against a molecule that, in most cases, is saving the life […] May 24, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2017 German Biotech Tops Up its Oncolytic Virus with Immuno-Oncology Drugs Oryx has reported good clinical data on the combination of its oncolytic virus with immuno-oncology drugs, convincing the biotech to start clinical trials. Based in Munich, Oryx is developing cancer immunotherapies for a number of solid tumors consisting of oncolytic viruses and peptide vaccines. The company just announced positive clinical data for 16 patients treated under compassionate use […] May 23, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2017 Merck to Pay Ablynx €15M for Getting a Second Nanobody ready for the Clinic Ablynx is receiving its first milestone payment from a deal with Merck for the development of first-in-class treatments for osteoarthritis. Belgium-based Ablynx develops nanobodies, molecules with the same properties as antibodies but with the advantage of being much smaller. This technology has attracted top pharma partners like AbbVie, MSD, Boehringer Ingelheim and Novartis. Now, the third […] May 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 May 2017 Norwegian Biotech Goes for Combination Therapies in Melanoma BerGenBio has started a new Phase I/II trial evaluating the addition of its Axl inhibitor to standard of care treatments in advanced melanoma. In March, Norwegian BerGenBio beat a biotech record on the Norwegian stock exchange, raising a massive €43.55M. Now, the company is standing by its promises and just dosed the first patient in a […] May 22, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 22 May 2017 UPDATE: Argenx’s IPO soars to over €100M to prove itself in Phase II UPDATE (22/05/2017): Argenx has gone above and beyond to secure $115M (€103M) on the NASDAQ. Underwriters claimed all of the shares offered in over allotment, bringing the IPO to 50% more than the initial goal. Rather a lot for a company whose compound has yet to prove itself in Phase II. UPDATE (24/04/2017): Pricing terms have yet to be set, but the […] May 22, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 22 May 2017 Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer Arthur Lahr, CEO of Kiadis Pharma, explains the promising cell therapy the company is developing and discusses how the dutch biotech ecosystem has evolved. Arthur Lahr has been part of the Dutch biotech scene for over 15 years now. The former Chief Strategy Officer of Crucell, which was sold to J&J in 2011, is now […] May 22, 2017 - 7 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 May 2017 A Concert Played by Human Neurons on a Petri Dish Guy Ben-Ary grew his own neurons on a Petri dish and made them perform in a concert last weekend at the Haus der Kulturen der Welt in Berlin. Last weekend I took my bike across Berlin to attend a truly unique event. It was, in fact, my first time going to a concert where one […] May 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 19 May 2017 The EMA Grants Priority to an Enzyme to Avoid Liver Transplant Rejection Hansa Medical has accessed the EMA’s priority medicines scheme to accelerate the development of a therapy that broadens the access to kidney transplants. Hansa Medical, based in Lund, Sweden, develops enzymes with immunomodulatory properties. Its lead candidate, IdeS, has now been granted access to the EMA’s priority medicines (PRIME) scheme, designed to support the development […] May 19, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email